| Date Filed | Type | Description |
| 10/04/2023 |
4
| Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Sold 2,942 shares
@ $12.68, valued at
$37.3k
|
|
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 08/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/12/2023 |
4
| Friedman Franklin Stuart (Director) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Bought 10,000 shares
@ $13.8828, valued at
$138.8k
|
|
| 05/03/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 05/03/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/03/2023 |
8-K
| Quarterly results |
| 04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/23/2023 |
4
| Hoerter Steven L. (President and CEO) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Sold 7,500 shares
@ $15.5709, valued at
$116.8k
|
|
| 03/22/2023 |
SC 13G
| Flynn James E reports a 6.1% stake in Deciphera Pharmaceuticals, Inc. |
| 03/01/2023 |
4
| Brightstar Associates LLC (10% Owner) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Exercised (in-or-at-the-money) 2,427,693 warrants
@ $0.01, valued at
$24.3k
|
|
| 02/14/2023 |
SC 13G
| BRAIDWELL LP reports a 6.7% stake in DECIPHERA PHARMACEUTICALS INC |
| 02/14/2023 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 7.6% stake in DECIPHERA PHARMACEUTICALS, INC. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| Flynn James E reports a 3.5% stake in Deciphera Pharmaceuticals, Inc. |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 7% stake in Deciphera Pharmaceuticals Inc. |
| 02/08/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2023 |
SC 13G/A
| GOLDMAN SACHS GROUP INC reports a 5.7% stake in DECIPHERA PHARMACEUTICALS, INC. |
| 02/07/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/07/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/07/2023 |
8-K
| Quarterly results |
| 02/03/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/24/2023 |
4
| Brightstar Associates LLC (10% Owner) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Bought 1,666,666 shares
@ $18, valued at
$30M
|
|
| 01/20/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 01/20/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 01/19/2023 |
4
| Friedman Franklin Stuart (Director) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Granted 3,269 options to buy
@ $21.27, valued at
$69.5k
|
|
| 01/19/2023 |
4
| Flynn Daniel Lee (Chief Scientific Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Sold 2,403 shares
@ $21.2413, valued at
$51k
|
|
| 01/19/2023 |
4
| Pitman Jama (See Remarks) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Sold 1,603 shares
@ $21.2413, valued at
$34k
|
|
| 01/19/2023 |
4
| Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Sold 2,403 shares
@ $21.2413, valued at
$51k
|
|
| 01/19/2023 |
4
| Allen Patricia L (Director) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Granted 3,269 options to buy
@ $21.27, valued at
$69.5k
|
|
|